The North America sepsis diagnostics market is expected to grow from US$ 279.06 million in 2021 to US$ 513.33 million by 2028. It is estimated to record a CAGR of 9.1% from 2021 to 2028.

High Incidence of Sepsis due to Increasing Nosocomial Infections Drives North America Sepsis Diagnostics Market

Sepsis, fundamentally caused by infection, predominantly affects immunocompromised individuals like those undergoing chemotherapy, post-splenectomy patients, and those with AIDS or chronic conditions such as diabetes. Among various infections, nosocomial infections are a leading cause of illness and death in hospitalized patients. The Centers for Disease Control and Prevention (CDC)'s "2020 National and State Healthcare-Associated Infections Progress Report" (published 2021) indicated significant increases in US healthcare-associated infections from 2019 to 2020: central line-associated bloodstream infections rose by approximately 24%, ventilator-associated events by 35%, and Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia by 15%.

The Global Sepsis Alliance (GSA) estimates that around 26 million people worldwide develop sepsis annually, leading to approximately 8 million deaths. Many of these fatalities, often linked to diarrheal diseases or lower respiratory infections, are preventable with timely diagnosis and effective clinical management. Consequently, the escalating incidence of bloodstream infections and the high overall rate of sepsis are expected to fuel the demand for sepsis diagnostic products, thereby propelling the growth of the North America sepsis diagnostics market during the forecast period.

Download our Sample PDF Report

@ https://www.businessmarketinsights.com/sample/BMIRE00025664

North America Sepsis Diagnostics Strategic Insights

North America Sepsis Diagnostics Strategic Insights offers a data-driven examination of the industry landscape, encompassing current trends, major players, and distinct regional characteristics. These insights provide practical guidance, allowing readers to differentiate themselves from rivals by pinpointing unaddressed market segments or creating unique value propositions. Utilizing data analytics, these insights assist industry players—including investors, manufacturers, and other stakeholders—in foreseeing market shifts. A forward-looking perspective is crucial for stakeholders to anticipate market dynamics and secure long-term success in this evolving regional market. Ultimately, robust strategic insights empower readers to make knowledgeable decisions that boost profitability and help them achieve their business objectives within the market.

North America Sepsis Diagnostics Market Segmentation

North America Sepsis Diagnostics Market By Product

Instruments

Reagents and Assays

Blood Culture Media

Software

North America Sepsis Diagnostics Market By Technology

Molecular Diagnostics

By Flow Cytometry, Microfluidics, Immunoassay, Biomarkers, Microbiology)

North America Sepsis Diagnostics Market By Method

Automated Diagnostics and Conventional Diagnostics

North America Sepsis Diagnostics Market By Test Type

Point-of-Care Tests and Laboratory Tests

North America Sepsis Diagnostics Market Regions and Countries Covered          

North America

US

Canada

Mexico

North America Sepsis Diagnostics Market  leaders and key company profiles     

Abbott

BD

bioMerieux SA

Danaher (Beckman Coulter)

1. HOFFMANN-LA ROCHE LTD.

Immunexpress Inc.

Luminex Corporation

T2 Biosystems, Inc.

THERMO FISHER SCIENTIFIC INC.

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications